Cubicin 500mg powder for solution for injection or infusion

  • Name:

    Cubicin 500mg powder for solution for injection or infusion

  • Company:
    info
  • Active Ingredients:

    Daptomycin

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 30/08/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 18/1/2019

Click on this link to Download PDF directly

MSD Ireland (Human Health) Limited

MSD Ireland (Human Health) Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Adempas Film Coated Tablets Active Ingredients Riociguat
Medicine Name Arcoxia 30 60 90 120 film-coated tablets Active Ingredients Etoricoxib
Medicine Name Atozet 10mg/10mg, 10mg/20mg, 10mg/40mg and 10mg/80mg film-coated tablets Active Ingredients Atorvastatin calcium trihydrate, ezetimibe
Medicine Name Bridion Active Ingredients Sugammadex sodium
Medicine Name Cancidas 50mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cancidas 70mg Powder for concentrate for solution for infusion Active Ingredients caspofungin acetate
Medicine Name Cerazette 75 microgram film-coated tablet Active Ingredients Desogestrel
Medicine Name Cozaar 12.5mg, 50mg & 100mg Film-coated Tablets Active Ingredients Losartan potassium
Medicine Name Cozaar 2.5mg/ml Powder and Solvent for Oral Suspension Active Ingredients Losartan potassium
Medicine Name Cozaar COMP 50 mg/12.5 mg, 100 mg/12.5 mg, 100 mg/25 mg film-coated tablets Active Ingredients Hydrochlorothiazide, Losartan potassium
Medicine Name Cubicin 350mg Powder for Solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Cubicin 500mg powder for solution for injection or infusion Active Ingredients Daptomycin
Medicine Name Delstrigo 100 mg/300 mg/245 mg film-coated tablets Active Ingredients Lamivudine, Tenofovir disoproxil fumarate, Doravirine
Medicine Name Diprosalic Scalp Application Active Ingredients Betamethasone dipropionate, Salicylic Acid
Medicine Name Elocon Cream Active Ingredients Mometasone Furoate
Medicine Name Elocon Ointment Active Ingredients Mometasone Furoate
Medicine Name Elocon Scalp Lotion Active Ingredients Mometasone Furoate
Medicine Name EMEND 125 mg hard capsules Active Ingredients Aprepitant
Medicine Name EMEND 80 mg hard capsules Active Ingredients Aprepitant
Medicine Name EMEND 80mg, 125mg hard Capsules Active Ingredients Aprepitant
Medicine Name Esmeron Active Ingredients Rocuronium Bromide
Medicine Name EZETROL 10 mg Tablets Active Ingredients ezetimibe
Medicine Name FOSAMAX Once Weekly 70 mg Tablets Active Ingredients Alendronate Sodium Trihydrate
Medicine Name FOSAVANCE Active Ingredients Alendronate Sodium Trihydrate, Colecalciferol (Vitamin D3)
Medicine Name GARDASIL Active Ingredients human papillomavirus vaccine
1 - 0 of 84 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18 January 2019 SmPC

Reasons for updating

  • Change to section 9 - Date of first authorisation/renewal of the authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Editorial update to correct date of latest renewal in section 9 of the SPC

 

Updated on 30 August 2018 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 30 August 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to Marketing Authorisation Holder name and address in section 7 of the SPC.

Updated on 16 July 2018 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 4.8 of the SPC to add the adverse reaction: Thrombocytopaenia

Updated on 16 July 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 12 March 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 12 March 2018 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Update to section 4.8 of the SPC to add the adverse events: leukocytosis, muscle cramps and eye irritation. Editorial updates to section 5.1 of the SPC

Updated on 8 March 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 8 March 2018 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 11 December 2017 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text
  • Change from individual to joint SPC

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated to extend the Staphylococcus aureus bacteraemia indication to include paediatric patients 1 to 17 years of age.  

In addition, the SPCs for the 350mg and 500mg strength have been combined together into one document and the SPC has been updated in line with the latest QRD template version 10.

Updated on 7 December 2017 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Correction of spelling/typing errors

Updated on 6 December 2017 PIL

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 6 - date of revision
  • Change to information for healthcare professionals
  • Correction of spelling/typing errors

Updated on 16 August 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of text regarding organising pneumonia to sections 4.4 and 4.8.

A number of editorial amendments were made to sections 5.1 and 5.2.

Updated on 18 July 2016 PIL

Reasons for updating

  • Change of manufacturer

Updated on 8 July 2016 PIL

Reasons for updating

  • Change to side-effects
  • Change to date of revision

Updated on 6 July 2016 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Updates to Section 4.8 -Undesirable effects and Section 10 – Date of revision of the the text following the approval of PSUR (PSUSA 931-201509)

Updated on 9 June 2016 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The changes are:

Transfer of Marketing Authorisation from

 

Novartis Europharm Limited                       to:                          Merck Sharp & Dohme Ltd

Frimley Business Park                                                                    Hertford Road, Hoddesdon        

Camberley GU16 7SR                                                                     Hertfordshire EN11 9BU

United Kingdom                                                                               United Kingdom

Updated on 9 June 2016 PIL

Reasons for updating

  • Change of manufacturer
  • Change to further information section
  • Change to date of revision
  • Change to marketing authorisation holder
  • Change to MA holder contact details

Updated on 21 January 2016 PIL

Reasons for updating

  • Change to dosage and administration

Updated on 1 December 2015 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Updated to extend the cSSSI indication of Cubicin to paediatric patients (1 to 17 years of age).

Updated on 23 July 2015 PIL

Reasons for updating

  • Change to dosage and administration
  • Change to MA holder contact details

Updated on 25 June 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.3 - Preclinical safety data
  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

·         Update Sections 4.4 and 5.3 of the EU SmPC with additional preclinical information from a neonatal dog study

·         Update Section 6.6 to include more detail to describe the technique to reconstitute lyophilised Cubicin

·         Update Section 7 to reflect the change in the address of the MAH from “Novartis Europharm Limited, Horsham, UK” to “Novartis Europharm Limited, Frimley Business Park, UK”

Updated on 11 June 2014 PIL

Reasons for updating

  • Change to appearance of the medicine
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 27 May 2014 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Correct date of revision from May 2014 to April 2014

Updated on 21 May 2014 SmPC

Reasons for updating

  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

·         Removal of cautionary statement about use in elderly patients from SPC Section 4.2

·         Update the drug product appearance from “lyophilised powder” to “lyophilised cake or powder” to in SPC Section 3

·         Addition of the reporting requirements for adverse events to SPC Section 4.8

Updated on 4 July 2013 PIL

Reasons for updating

  • Change of manufacturer

Updated on 17 September 2012 PIL

Reasons for updating

  • Change to side-effects
  • Change to improve clarity and readability

Updated on 29 February 2012 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Following new adverse reactions in Section 4.8 (frequency “not known” as based on post marketing reports):

·         Angioedema

·         Drug rash with eosinophilia and systemic symptoms (DRESS)

·         Cough

Updated on 23 March 2011 PIL

Reasons for updating

  • Change to side-effects

Updated on 2 March 2011 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Inclusion of warning on eosinophilic pneumonia

Updated on 5 October 2009 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 9 December 2008 PIL

Reasons for updating

  • Correction of spelling/typing errors
  • Change to date of revision

Updated on 17 April 2007 PIL

Reasons for updating

  • New PIL for new product